Credit Suisse Ag Taysha Gene Therapies, Inc. Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TSHA
# of Institutions
117Shares Held
136MCall Options Held
25.9KPut Options Held
24K-
Avoro Capital Advisors LLC New York, NY18.7MShares$32.8 Million0.56% of portfolio
-
Rtw Investments, LP New York, NY14.9MShares$26.3 Million0.48% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$20.7 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$19.1 Million0.3% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$15.8 Million1.87% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $85.1M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...